Charles Schwab
TTPH

Charles Schwab’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Charles Schwab’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,033
Closed -$135K – 3298
2019
Q1 		$135K Sell
5,033
-2,743
-35% -$69.8K ﹤0.01% 3068
2018
Q4 		$176K Buy
7,776
+1,965
+34% +$76.8K ﹤0.01% 3034
2018
Q3 		$321K Sell
5,811
-7,971
-58% -$509K ﹤0.01% 2989
2018
Q2 		$984K Buy
13,782
+1,167
+9% +$82.4K ﹤0.01% 2591
2018
Q1 		$775K Buy
12,615
+422
+3% +$37K ﹤0.01% 2600
2017
Q4 		$1.54M Buy
12,193
+1,339
+12% +$171K ﹤0.01% 2394
2017
Q3 		$1.49M Buy
10,854
+4,370
+67% +$584K ﹤0.01% 2393
2017
Q2 		$925K Buy
6,484
+44
+0.7% +$6.8K ﹤0.01% 2482
2017
Q1 		$1.18M Buy
6,440
+393
+6% +$44.1K ﹤0.01% 2377
2016
Q4 		$488K Buy
6,047
+354
+6% +$28K ﹤0.01% 2656
2016
Q3 		$437K Buy
5,693
+20
+0.4% +$1.6K ﹤0.01% 2660
2016
Q2 		$488K Buy
5,673
+93
+2% +$8.52K ﹤0.01% 2596
2016
Q1 		$517K Buy
5,580
+112
+2% +$11.2K ﹤0.01% 2567
2015
Q4 		$1.1M Sell
5,468
-1,131
-17% -$226K ﹤0.01% 2355
2015
Q3 		$985K Buy
6,599
+3,716
+129% +$2.73M ﹤0.01% 2389
2015
Q2 		$2.74M Buy
2,883
+733
+34% +$599K ﹤0.01% 1918
2015
Q1 		$1.58M Buy
2,150
+280
+15% +$210K ﹤0.01% 2183
2014
Q4 		$1.49M Buy
1,870
+255
+16% +$137K ﹤0.01% 2169
2014
Q3 		$645K Hold
1,615
– – ﹤0.01% 2497
2014
Q2 		$436K Buy
1,615
+480
+42% +$103K ﹤0.01% 2684
2014
Q1 		$248K Buy
1,135
+315
+38% +$87.8K ﹤0.01% 2879
2013
Q4 		$222K Hold
820
– – ﹤0.01% 2928
2013
Q3 		$194K Hold
820
– – ﹤0.01% 2925
2013
Q2 		$120K Buy
+820
New +$130K ﹤0.01% 3012

Other funds holding TTPH

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Charles Schwab's TTPH Position: Q2 2019 in Review

Charles Schwab sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2019, closing a stake of 5,033 shares — an estimated $135K sold.

Charles Schwab first reported a position in TTPH in Q2 2013 and held it in 24 quarters. The position peaked at $2.74M in Q2 2015. 66 funds tracked by Wall St. Rank hold TTPH as of Q2 2019.

  • Charles Schwab reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Charles Schwab sold 5,033 Tetraphase Pharmaceuticals, Inc. shares in Q2 2019, an estimated $135K.
  • Charles Schwab first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 24 quarters.
  • Charles Schwab's Tetraphase Pharmaceuticals, Inc. position peaked at $2.74M in Q2 2015.
  • 66 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2019.

Based on Charles Schwab's 13F filing for Q2 2019, filed 9 Aug 2019.